158 related articles for article (PubMed ID: 32193054)
1. p62 as a therapeutic target for tumor.
Tao M; Liu T; You Q; Jiang Z
Eur J Med Chem; 2020 May; 193():112231. PubMed ID: 32193054
[TBL] [Abstract][Full Text] [Related]
2. p62/SQSTM1/A170: physiology and pathology.
Komatsu M; Kageyama S; Ichimura Y
Pharmacol Res; 2012 Dec; 66(6):457-62. PubMed ID: 22841931
[TBL] [Abstract][Full Text] [Related]
3. p62 at the interface of autophagy, oxidative stress signaling, and cancer.
Nezis IP; Stenmark H
Antioxid Redox Signal; 2012 Sep; 17(5):786-93. PubMed ID: 22074114
[TBL] [Abstract][Full Text] [Related]
4. p62/SQSTM1, a Central but Unexploited Target: Advances in Its Physiological/Pathogenic Functions and Small Molecular Modulators.
Chen Y; Li Q; Li Q; Xing S; Liu Y; Liu Y; Chen Y; Liu W; Feng F; Sun H
J Med Chem; 2020 Sep; 63(18):10135-10157. PubMed ID: 32324396
[TBL] [Abstract][Full Text] [Related]
5. p62/SQSTM1: 'Jack of all trades' in health and cancer.
Sánchez-Martín P; Saito T; Komatsu M
FEBS J; 2019 Jan; 286(1):8-23. PubMed ID: 30499183
[TBL] [Abstract][Full Text] [Related]
6. p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming.
Saito T; Ichimura Y; Taguchi K; Suzuki T; Mizushima T; Takagi K; Hirose Y; Nagahashi M; Iso T; Fukutomi T; Ohishi M; Endo K; Uemura T; Nishito Y; Okuda S; Obata M; Kouno T; Imamura R; Tada Y; Obata R; Yasuda D; Takahashi K; Fujimura T; Pi J; Lee MS; Ueno T; Ohe T; Mashino T; Wakai T; Kojima H; Okabe T; Nagano T; Motohashi H; Waguri S; Soga T; Yamamoto M; Tanaka K; Komatsu M
Nat Commun; 2016 Jun; 7():12030. PubMed ID: 27345495
[TBL] [Abstract][Full Text] [Related]
7. p62/SQSTM1 functions as a signaling hub and an autophagy adaptor.
Katsuragi Y; Ichimura Y; Komatsu M
FEBS J; 2015 Dec; 282(24):4672-8. PubMed ID: 26432171
[TBL] [Abstract][Full Text] [Related]
8. p62: Friend or Foe? Evidences for
Emanuele S; Lauricella M; D'Anneo A; Carlisi D; De Blasio A; Di Liberto D; Giuliano M
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708719
[TBL] [Abstract][Full Text] [Related]
9. The ICP0 Protein of Herpes Simplex Virus 1 (HSV-1) Downregulates Major Autophagy Adaptor Proteins Sequestosome 1 and Optineurin during the Early Stages of HSV-1 Infection.
Waisner H; Kalamvoki M
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375597
[TBL] [Abstract][Full Text] [Related]
10. Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulation.
Battista RA; Resnati M; Facchi C; Ruggieri E; Cremasco F; Paradiso F; Orfanelli U; Giordano L; Bussi M; Cenci S; Milan E
PLoS One; 2018; 13(8):e0201621. PubMed ID: 30067838
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
12. Staurosporine alleviates cisplatin chemoresistance in human cancer cell models by suppressing the induction of SQSTM1/p62.
Alsamman K; El-Masry OS
Oncol Rep; 2018 Oct; 40(4):2157-2162. PubMed ID: 30106434
[TBL] [Abstract][Full Text] [Related]
13. p62 in Cancer: Signaling Adaptor Beyond Autophagy.
Moscat J; Karin M; Diaz-Meco MT
Cell; 2016 Oct; 167(3):606-609. PubMed ID: 27768885
[TBL] [Abstract][Full Text] [Related]
14. SQSTM1/p62 and Hepatic Mallory-Denk Body Formation in Alcohol-Associated Liver Disease.
Qian H; Ding WX
Am J Pathol; 2023 Oct; 193(10):1415-1426. PubMed ID: 36906265
[TBL] [Abstract][Full Text] [Related]
15. p62/SQSTM1 protects against cisplatin-induced oxidative stress in kidneys by mediating the cross talk between autophagy and the Keap1-Nrf2 signalling pathway.
Liao W; Wang Z; Fu Z; Ma H; Jiang M; Xu A; Zhang W
Free Radic Res; 2019 Jul; 53(7):800-814. PubMed ID: 31223046
[TBL] [Abstract][Full Text] [Related]
16. Negative Regulation of the Keap1-Nrf2 Pathway by a p62/Sqstm1 Splicing Variant.
Kageyama S; Saito T; Obata M; Koide RH; Ichimura Y; Komatsu M
Mol Cell Biol; 2018 Apr; 38(7):. PubMed ID: 29339380
[TBL] [Abstract][Full Text] [Related]
17. Sequestosome 1/p62-related pathways as therapeutic targets in hepatocellular carcinoma.
Denk H; Stumptner C; Abuja PM; Zatloukal K
Expert Opin Ther Targets; 2019 May; 23(5):393-406. PubMed ID: 30987486
[TBL] [Abstract][Full Text] [Related]
18. Normal pancreatic β-cell function in mice with RIP-Cre-mediated inactivation of p62/SQSTM1.
Honda A; Komiya K; Hara A; Fukunaka A; Suzuki L; Miyatsuka T; Ogihara T; Fujitani Y; Watada H
Endocr J; 2018 Jan; 65(1):83-89. PubMed ID: 28978813
[TBL] [Abstract][Full Text] [Related]
19. p62/
Jeong SJ; Zhang X; Rodriguez-Velez A; Evans TD; Razani B
Antioxid Redox Signal; 2019 Aug; 31(6):458-471. PubMed ID: 30588824
[No Abstract] [Full Text] [Related]
20. Metabolic reprogramming of the tumor microenvironment by p62 and its partners.
Reina-Campos M; Shelton PM; Diaz-Meco MT; Moscat J
Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):88-95. PubMed ID: 29702207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
